Amplia announces A$25m Placement and Launches A$2.5m SPP
Released
Released
Announcement PDF
ABN 16 165 160 841
ASX RELEASE
23 JULY 2025
AMPLIA ANNOUNCES A$25 MILLION PLACEMENT AND LAUNCHES A$2.5 MILLION SPP
HIGHLIGHTS
•
Capital raise of $27.5 million (the Capital Raise) to support the ACCENT and AMPLICITY trials
and support kRAS and ovarian cancer trials of the Company’s lead drug, narmafotinib
(AMP945).
•
The Capital Raise comprises:
an institutional placement to raise A$25 million (Placement); and
a Share Purchase Plan seeking to raise an additional A$2.5 million (SPP).
•
New Shares issued under the Placement are priced at $0.23 each (Placement Offer Price).
•
The Placement was strongly supported by existing and new institutional and sophisticated
investors in Australia and offshore
•
Firm commitments received from institutional investors for A$2.5 million worth of shortfall
shares under the SPP (in the event of a shortfall).
•
Top-line data from the ACCENT trial is expected in late July/early August 2025
•
Funds from the Capital Raise will enable the company to accelerate towards commencement
of a potential pivotal phase 2b/3 trial in 2H 2026
•
Following the Capital Raise the company will be funded into 2027.
Melbourne, Australia: Amplia Therapeutics Limited (ASX: ATX), (Amplia or the Company), is pleased
to announce that it has undertaken a successful A$25.0 million institutional placement (Placement) of
new, fully paid ordinary shares in the Company (New Shares) at a price of $0.23 per New Share
(Placement Offer Price).
The Placement will be followed by a share purchase plan (SPP) seeking to raise $2.5 million (with the
ability to accept over-subscriptions of up to an additional $7.5 million) at the SPP offer price. Amplia
has received firm commitments for $2.5 million worth of shortfall shares under the SPP (in the event
of a shortfall).
Commenting on the successful Capital Raise, Amplia Managing Director Dr Chris Burns commented:
“We are extremely grateful for the support in this raise from our existing institutional and sophisticated
investors, as well as from the new investors. The funds from the raise will support our ongoing clinical
studies, along with planning for follow-on trials, to build on the exciting data already obtained for
narmafotinib in the ACCENT study in pancreatic cancer.”
Level 17, 350 Queen Street, Melbourne VIC 3000
Email info@ampliatx.com
www.ampliatx.com
Placement
The Placement comprises the following components:
•
a placement utilising Amplia’s existing placement capacity to raise approximately $22.3 million
(Unconditional Placement) via the issue of:
o
57,937,087 New Shares under the Company’s Listing Rule 7.1 capacity; and
o
38,867,267 New Shares under the Company’s Listing Rule 7.1A capacity;
•
a placement to raise $2.5 million to two large existing institutional shareholders via the issue of
approximately 10.87 million New Shares, subject to shareholder approval for the purposes of
Listing Rule 7.1 (Conditional Placement); and
•
a placement to Amplia’s directors to raise $235,000 via the issue of approximately 1.02 million
New Shares, subject to shareholder approval for the purposes of Listing Rule 10.11 (Director
Placement).
The Placement Offer Price of $0.23 per New Share represents a:
•
discount of 19.3% to the closing price of Amplia shares on Friday, 18 July 2025 (of $0.285);
•
discount of 22.8% to the 5 trading day VWAP for the period ending Friday, 18 July 2025 (of
$0.298); and
•
premium of 0.6% to the 30 trading day VWAP for the period ending Friday, 18 July 2025 (of
$0.229).
Settlement of the New Shares to be issued under the Unconditional Placement is expected to take
place on Monday, 28 July 2025, with allotment and commencement of trading expected to occur on
Tuesday, 29 July 2025.
Approval will be sought for the Conditional Placement and Director Placement at Amplia’s Annual
General Meeting to be held on Wednesday, 27 August 2025 (AGM). Assuming shareholder approval is
obtained, settlement of the New Shares to be issued under the Conditional Placement and Director
Placement is expected to take place on Friday, 29 August 2025 with allotment and commencement of
trading expected to occur on Monday, 1 September 2025.
The Placement was strongly supported by new and existing domestic and international investors.
Share Purchase Plan
In conjunction with the Placement, the Company will offer existing shareholders the opportunity to
participate in the SPP, which is seeking to raise a further A$2.5 million.
Under the SPP, shareholders at 7:00pm (Sydney time) on the record date of Tuesday, 22 July with a
registered address in Australia or New Zealand (Eligible Shareholders) will be offered the opportunity
to apply for up to A$100,000 of New Shares without any brokerage or transaction costs.
The SPP is being undertaken at the SPP Offer Price¸ which is the lower of:
•
the Placement Offer Price (of $0.23); and
•
the price representing a discount of 5.0% to the VWAP of Amplia shares over the last 5 trading
days of the SPP offer period, rounded (up or down) to the nearest half-cent.
The SPP is conditional on Amplia shareholder approval for the purposes of Listing Rule 7.1. Approval
will be sought for the SPP at the AGM.
The SPP will be undertaken pursuant to a transaction-specific prospectus that is expected to be lodged
with ASIC and ASX and made available to Eligible Shareholders on Friday, 1 August 2025 (SPP Offer
Booklet).
The SPP is seeking to raise A$2.5 million. Applications in excess of this amount may be scaled back in
accordance with the scale back policy set out in the SPP Offer Booklet. In the event of a scale-back, any
excess money will be refunded (without interest). Amplia has received firm commitments for $2.5
million worth of shortfall shares under the SPP (in the event of a shortfall).
Amplia retains the discretion to accept over-subscriptions of up to an additional $7.5 million of New
Shares under the SPP.
The key dates for the SPP are set out in the timetable below.
Sources and Uses of Funds
Amplia intends to use its existing cash reserves, expected future R&D grants and the proceeds of the
Capital Raise in accordance with the Use of Funds table below.
Sources of Funds
AUD ($m)
Cash Balance (at 30 June 25) 1
$7.0
Expected FY25 and FY26 R&D Tax Refunds2
$8.2
Capital Raise
$27.5
Total
$42.7
1 Unaudited – based on 31 March 2025 Appendix 4C and management accounts
2 FY25 R&D tax refund expected August 2025 and FY26 R&D tax refund expected August 2026
Uses of Funds
ACCENT trial
• Completion of Phase 2a
• Foundational work for Phase 2b/3 trial
Amplicity trial
• Dose escalation
• 2 Dose comparison
AUD ($m)
$6.0
$19.0
KRAS and/or Ovarian trial
$5.0
CMC (manufacturing)
$6.0
Operations, preclinical, working capital and offer
costs
$6.7
Total
$42.7
Key Dates
The Capital Raise will be conducted according to the following indicative timetable:
Event
Date
Record Date for SPP (7.00pm, Melbourne time)
Tuesday, 22 July 2025
Announcement of Placement and SPP and Shares recommence
trading on ASX
Wednesday, 23 July 2025
Settlement of the Unconditional Placement
Monday, 28 July 2025
Allotment of New Shares issued under the Unconditional
Placement
Tuesday, 29 July 2025
SPP Offer Booklet made available to Eligible Shareholders
Opening Date of SPP
Friday, 1 August 2025
Closing Date of SPP
Friday, 22 August 2025
Announcement of results of SPP
Tuesday, 26 August 2025
AGM
Wednesday, 27 August 2025
Settlement of Conditional Placement & Director Placement
Issue of New Shares under the SPP
Allotment of New Shares issued under the Conditional
Placement and Director Placement
Normal ASX trading for New Shares issued under the SPP
commences
Friday, 29 August 2025
Monday, 1 September 2025
* Please note the dates set out above are indicative only and are subject to change. All dates and
times are references to Melbourne, Australia time.
Amplia reserves the right, subject to the Corporations Act 2001 (Cth) and the ASX Listing Rules, to
amend this indicative timetable. In particular, Amplia reserves the right to extend the closing date for
the SPP, accept late applications under the SPP (either generally or in particular cases) and to withdraw
the Placement or SPP without prior notice. Any extension of the closing date for the SPP will have a
consequential effect on the date for the issue of New Shares.
Other Information
Further information about the Placement, SPP and the Company (including a description of some of
the key risks involved in an investment in New Shares) can be found in the presentation lodged with
ASX on 22 July 2025, which is available on the ASX’s website (www.asx.com.au) and the Company’s
website (www.ampliatx.com).
Bell Potter Securities Limited acted as the sole Lead Manager to the Placement.
Evolution Capital Pty Ltd acted as Co-Manager to the Placement.
Becketts Lawyers acted as Australian legal adviser to Amplia.
The Company’s shares will recommence trading on the ASX today (23 July 2025).
This ASX announcement was approved and authorised for release by the Managing Director of Amplia
Therapeutics Limited.
Investor Contact:
Dr Chris Burns
Chief Executive Officer
chris@ampliatx.com
Media Contact:
H^CK Director, Haley Chartres
haley@hck.digital
+61 423 139 163
About Amplia Therapeutics Limited
Amplia Therapeutics Limited is an Australian pharmaceutical company advancing a pipeline of Focal
Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the
field of cancer and Amplia has a particular development focus in fibrotic cancers such as pancreatic
and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic
pulmonary fibrosis (IPF). For more information visit www.ampliatx.com and follow Amplia on Twitter
(@ampliatx), and LinkedIn.
IMPORTANT INFORMATION
This announcement has been prepared for publication in Australia and may not be released to U.S.
wire services or distributed in the United States. This announcement does not constitute an offer to
sell, or a solicitation of an offer to buy, securities in the United States or any other jurisdiction. Any
securities described in this announcement have not been, and will not be, registered under the U.S.
Securities Act of 1933 and may not be offered or sold in the United States except in transactions
exempt from, or not subject to, registration under the U.S. Securities Act and applicable U.S. state
securities laws.
Share your feedback
Discover